Patent intelligence · US
US 6582697
Enhancement of the cellular immune response
Enhancement of the cellular immune response
Patent details — US 6582697
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jun 24, 2003
- Expiration
- Jun 19, 2023
- Applicant
- Biomira, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K39/001169, A61K45/05, A61K47/646
Quick answer
US 6582697 (Enhancement of the cellular immune response) is held by Biomira, Inc.. Status: expired. Granted Jun 24, 2003. Expires Jun 19, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Biomira, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K39/001169, A61K45/05, A61K47/646
More from Biomira, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 6582697?
US 6582697 (Enhancement of the cellular immune response) is held by Biomira, Inc.. Status: expired. Granted Jun 24, 2003. Expires Jun 19, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6582697?
Biomira, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 6582697 expire?
Our index shows an expiration date of Jun 19, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.